Importation of Controlled Substances; Application

Pursuant to section 1008 of the Controlled Substances Import and Export Act
(21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a
registration under this Section to a bulk manufacturer of a controlled
substance in Schedule I or II and prior to issuing a regulation under Section
1002(a) authorizing the importation of such a substance, provide manufacturers
holding registrations for the bulk manufacture of the substance an opportunity
for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal
Regulations (CFR), notice is hereby given that on November 2, 1993, The
Binding Site, Inc., 5889 Oberlin Drive, Suite 101, San Diego, California
92121, made application to the Drug Enforcement Administration to be
registered as an importer of the basic classes of controlled substances listed
below:

c2,L2,tp0,i1,s25,xls20

  [col head 1] Drug [col head 1] Schedule

Methaqualone (2565) 	I

Lysergic acid diethylamid (7315) 	I

Tetrahydrocannabinols (7370) 	I

Normorphine (9313) 	I

Amphetamine (1100) 	II

Methamphetamine (1105) 	II

Amobarbital (2125) 	II

Phencyclidine (7471) 	II

Cocaine (9041) 	II

Ethylmorphine (9190) 	II

Methadone-intermediate (9254) 	II

The firm plans to import the above listed substances in milligram quantities
for labelling with enzymes, fluorophores and radioisotopes for immunoassays.

Any manufacturer holding, or applying for, registration as a bulk manufacturer
of this basic class of controlled substance may file written comments on or
objections to the application described above and may, at the same time, file
a written request for a hearing on such application in accordance with 21 CFR
1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to
the Director, Office of Diversion Control, Drug Enforcement Administration,
United States Department of Justice, Washington, D.C. 20537, Attention: DEA
Federal Register Representative (CCR), and must be filed no later than January
27, 1994.

This procedure is to be conducted simultaneously with and independent of the
procedures described in 21 CFR 1311.42(b), (c), (d), (e), and (f). As noted in
a previous notice at 40 FR 43745Ä46 (September 23, 1975), all applicants for
registration to improt a basic class of any controlled substance in Schedule I
or II are and will continue to be required to demonstrate to the Director,
Office of Diversion Control, Drug Enforcement Administration that the
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C.
823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: December 21, 1993.

Gene R. Haislip,

Director, Office of Diversion Control Drug Enforcement Administration.

[FR Doc. 93Ä31613 Filed 12Ä27Ä93; 8:45 am]

BILLING CODE 4410Ä09ÄM